Defective X-gating caused by de novo gain-of-function mutations in KCNK3 underlies a developmental disorder with sleep apnea

Competing Interest Statement

M.G.H and T.M are employees of Bayer, AG. A.B. and R.W. are employees of GeneDx, Inc. M.E.H. is Scientific Director of Congenica. No other conflicts are declared

Funding Statement

Funded by grants from the BBSRC, Wellcome Trust and DFG.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethic committee approvals are available from all participating institutions. For the original study (Kaplanis et al, Nature 2020), lead institution approval was obtained by the UK Ethics Research Committee.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes